The FDA has stated its position on exosome products plainly and repeatedly: no exosome products are currently approved for human use. Most clinic owners have heard this. Fewer understand what it actually means for their marketing. The result is two common mistakes. Either the clinic markets exosomes as if they were approved, or it avoids the topic entirely because the rules feel unclear.
TLDR: There are currently no FDA-approved exosome products. Exosomes intended to treat diseases are regulated as drugs and biological products requiring premarket approval. None have been approved. That does not make exosome services automatically illegal. It makes specific marketing claims the source of enforcement risk. Clinics can still describe what exosomes are, how the procedure works, and what the research shows. They cannot make disease treatment claims, imply FDA approval, or use testimonials describing condition resolution.
Important Note
This article is for educational purposes only and does not constitute legal, medical, or regulatory advice. Marketing strategies discussed should be reviewed by qualified legal counsel before implementation, particularly regarding FDA, FTC, and state-specific advertising regulations. Regen Portal is a marketing company, not a law firm or compliance consultancy.
The FDA’s position on exosome products has not changed since the agency’s 2019 Public Safety Notification. It has been reaffirmed in consumer alerts, restated in safety communications, and enforced through warning letters issued as recently as 2025.
Most clinic owners who offer exosome services are not bad actors. They are operating in a space where supplier marketing, industry conferences, and competitor websites all use language that the FDA has flagged as creating enforcement risk. Knowing what the rules actually say is the first step toward marketing that grows the practice without creating exposure.
The question this article answers is not whether exosomes are approved. They are not. The question is what a clinic can actually say in its marketing without crossing into the language the FDA has cited in warning letters.
The FDA’s Current Position on Exosome Products
The FDA’s Public Safety Notification on Exosome Products states the position directly. There are no FDA-approved exosome products. Exosomes intended to treat diseases or conditions in humans are regulated as drugs and biological products, which means they require premarket review and approval before they can be marketed for clinical use.
The FDA’s Consumer Alert on Regenerative Medicine Products reaffirms this position. The agency tells consumers there are currently no FDA-approved exosome products, that exosome products intended to treat diseases require FDA approval, and that patients should ask for an IND number before treatment.
The agency has continued enforcement activity. Public warning letters have been issued to exosome product distributors and manufacturers, with the most recent cases appearing in 2025. The pattern is consistent.
Most clinic owners read this and conclude that offering exosome services is itself a violation. That is not accurate. The enforcement focus is on three things:
- Marketing exosome products with disease treatment claims
- Distribution of exosome products without an approved BLA or IND
- Failure to meet 21 CFR 1271 criteria when the product is positioned as a 361 HCT/P
The act of administration is a separate question from the marketing claims that surround it. The marketing is where most of the clinic-side exposure lives. For specific compliance questions about your protocols, consult qualified legal counsel.
Why the FDA Regulates Exosomes as Drugs
The FDA’s regulatory logic is straightforward once you understand the framework. Exosomes are extracellular vesicles. They are not cells. They do not replicate. They carry signaling molecules including proteins, lipids, and RNA that can affect recipient cell behavior.
When an exosome product is intended to treat, cure, or mitigate a disease or condition, it meets the definition of a drug under the FD&C Act. It also meets the definition of a biological product under the Public Health Service Act. That dual classification triggers the requirement for premarket approval through a BLA or IND.
The next question is whether the product could be regulated solely under 21 CFR 1271 as a 361 HCT/P. For most allogeneic exosome products, the answer is no. Two reasons.
First, the homologous use criterion. Under 21 CFR 1271.10(a)(2), the HCT/P must be intended for homologous use, meaning the product performs the same basic function in the recipient as in the donor. Exosomes derived from umbilical cord, amniotic fluid, or other donor sources do not perform the same basic function in a recipient receiving them for joint pain, neurological conditions, or aesthetic indications. The homologous use criterion fails.
Second, minimal manipulation. The processing required to isolate exosomes from donor tissue often exceeds the minimal manipulation standard. When a product fails either criterion, it cannot be regulated solely under Section 361. The full premarket review framework applies.
Autologous exosome procedures present a different regulatory picture. The analysis is more nuanced and not fully settled. Do not assume autologous protocols sit outside FDA jurisdiction without qualified legal review.
What this means for your practice: The reason exosome marketing is restrictive is not arbitrary. The product is legally a drug until proven otherwise through the approval process. No approval currently exists. Marketing it as a treatment is marketing an unapproved drug.
What the Warning Letter Pattern Tells Clinic Owners
FDA warning letters to exosome product manufacturers and distributors follow a consistent pattern. Three categories of violation appear in nearly every letter.
Marketing Exosome Products for Specific Disease Conditions
The most cited violation. The product’s website, promotional materials, or supplier-facing labeling stated or implied the product was intended to treat arthritis, joint injury, neurological conditions, aging, or other specific conditions. That intent caused the product to be classified as a drug requiring approval.
Failure to Meet the Homologous Use Standard
Allogeneic exosome products derived from donor tissue were marketed for uses that do not match the function the product performs in the donor. The 1271 criterion failed. The product could not be regulated solely as a 361 HCT/P. In some cases the FDA has treated exosome products as drugs outright, without analyzing them under the 1271 homologous use framework at all, because the products’ intended disease treatment use places them squarely in the drug classification regardless of tissue derivation.
Distribution Without an Approved BLA or IND
No currently marketed allogeneic exosome product has an approved BLA. Distribution without one, when the product is intended to treat a disease, violates section 505(a) of the FD&C Act.
What this means for your clinic: The violations are in the marketing claims and the intended use, not exclusively in the act of administration. A clinic that receives a product from a supplier operating in violation and then uses the same disease-treatment language in its own marketing creates parallel exposure for itself.
The Difference Between Exosome Marketing and PRP Marketing
Many clinics offer both PRP and exosome services and treat them as marketing-equivalent. They are not.
PRP is an autologous blood product. It is explicitly outside the scope of 21 CFR Part 1271 because blood products are excluded. It does not require a BLA. The compliance focus for PRP marketing is on disease treatment claims and off-label disclosure.
Exosome products operate under a different framework. Allogeneic exosome products require premarket approval to be marketed as treatments for diseases. No such approval currently exists for any commercially distributed exosome product.
This means the compliance baseline for exosome marketing is more restrictive than for PRP. Both require off-label disclosure when condition-specific applications are discussed. Both prohibit disease treatment claims. The difference is the additional layer for exosomes: the product’s unapproved drug status. Any implied treatment claim creates a compounding violation. The drug claim and the marketing of an unapproved drug stack on top of each other.
The Traffic Light Framework applies to both products, but the threshold for Red Light language in exosome marketing is lower. Language that might be Yellow Light for PRP gets closer to Red Light when applied to exosomes because the regulatory backdrop is more restrictive.
| Comparison Point | PRP | Exosome Products |
|---|---|---|
| Regulatory framework | Blood product, outside 21 CFR 1271 | Drug and biological product requiring premarket approval |
| FDA approval status | Some devices 510(k) cleared for bone graft handling; clinical applications off-label | No FDA-approved exosome products for human use |
| Marketing baseline | Off-label disclosure plus no disease claims | Off-label disclosure plus no disease claims plus no implication of approval |
| Compounding risk | Disease claim only | Disease claim plus unapproved drug marketing |
What Clinics Can Actually Say: The Compliant Marketing Framework
This is the practical core of the article. Most clinics overcorrect in one of two directions. They either market as if exosomes were approved, or they say nothing at all. Both approaches hurt the practice. There is a middle path.
What Clinics Can Say
Educational descriptions are Green Light. Clinics can describe what exosomes are at a biological level. Extracellular vesicles that carry signaling molecules. Active subjects of clinical research. Part of an evolving field.
Process descriptions are Green Light. What happens during the procedure. How the product is sourced or prepared. What the patient experience involves.
Research context is Green Light when accurate. That exosome-based therapies are a subject of active clinical research. That studies are ongoing. That the field continues to evolve. The line: describe the state of research without implying the specific product used in the clinic has been studied if it has not been.
Off-label disclosure is required. Any reference to clinical applications should clearly state that the service is offered as an off-label application that has not been approved by the FDA for any specific clinical indication. Patients should consult with the provider to determine whether the service is appropriate for their individual situation.
Consultation framing is the safest CTA pattern. “We offer consultations to discuss whether exosome therapy may be an option to explore for patients considering their choices” is compliant. “We treat [condition] with exosomes” is not. The same framing applies to Google Ads copy, where platform health policies add another layer of restriction on disease-specific claims.
Sourcing transparency builds trust without creating risk. Disclosing that the clinic uses products from suppliers who can provide Certificates of Analysis, donor screening documentation, and sterility testing is a trust signal. It is not a claim of efficacy or approval.
What Clinics Cannot Say
Direct disease treatment claims are Red Light. No statement that the product treats, cures, heals, or mitigates a specific disease or condition.
FDA approval implications are Red Light. No statement or implication that the product is FDA-approved or FDA-cleared for clinical use. “Sourced from an FDA-registered lab” does not mean the product is FDA-approved. The distinction must be explicit.
Disease outcome testimonials are Red Light. Even with FTC-compliant disclosure, testimonials describing condition resolution for an unapproved drug product remain high-risk. The safer position is to avoid them entirely for exosome services.
Equivalence comparisons are Red Light. Any comparison to approved therapies that implies equivalent regulatory standing creates misbranding risk.
Validation overreach is Red Light. Language that implies the off-label use has been validated by clinical trials, when the specific product has not been studied in such trials, creates substantiation risk under FTC health advertising standards.
Sourcing and Documentation: Why It Matters for Marketing
The compliance conversation for exosome marketing cannot stop at the clinic’s own language. The supplier matters.
A clinic that sources exosome products from a supplier who has received an FDA warning letter for marketing unapproved drugs inherits the exposure risk. The product itself may be subject to enforcement regardless of what the clinic says about it.
Documentation practices that reduce clinic exposure include sourcing from suppliers who can provide lot-level Certificates of Analysis, donor screening records, sterility testing documentation, and FDA registration information. A supplier who cannot provide these documents is a compliance liability regardless of how the supplier markets the product.
The clinic’s marketing should never describe sourcing in terms that imply FDA approval of the supplier’s product. FDA registration of a facility is not FDA approval of a product. Clinics that conflate the two in their marketing copy create misbranding risk independent of the supplier’s compliance posture.
How This Looks in Practice
A clinic was marketing exosome services with language describing the procedure as “regenerating damaged tissue” and “supporting recovery from joint injury.” The clinic sourced from a supplier whose website used similar language. Neither the clinic nor the supplier had reviewed the FDA’s Public Safety Notification or the warning letter pattern in the space.
After a compliance review that included a comparison of the clinic’s language against the FDA’s documented enforcement standards, the clinic made three changes. The “regenerating damaged tissue” language was replaced with a process description of what exosomes are and how the procedure is performed. The condition-specific landing page was replaced with a consultation-framing page that included off-label disclosure. The clinic requested documentation from the supplier including lot-level COAs and donor screening records.
No enforcement action. The changes addressed the exposure before any regulator reviewed the content. The clinic now markets its exosome services with full off-label disclosure and process-based language that describes the procedure without implying FDA-approved treatment outcomes.
The lesson is not that the clinic became less visible. The lesson is that it became more accurate, and that accuracy is what protects the practice.
Frequently Asked Questions
Are Any Exosome Products FDA Approved Right Now?
No. The FDA has stated repeatedly that there are no FDA-approved exosome products for human use. This position has been consistent since the agency’s 2019 Public Safety Notification.
Why Does the FDA Regulate Exosomes as Drugs?
When an exosome product is intended to treat or mitigate a disease, it meets the legal definition of a drug under the FD&C Act and a biological product under the PHS Act. That classification requires premarket approval before the product can be marketed for clinical use.
Is It Illegal for a Clinic to Offer Exosome Services?
The FDA’s enforcement focus is on the marketing of unapproved drug products and the failure of products to qualify as 361 HCT/Ps under 21 CFR 1271. The act of administration by a licensed provider is a separate question. Consult qualified legal counsel for specific protocols and state law considerations.
What Can a Clinic Actually Say About Exosome Therapy?
Clinics can describe what exosomes are biologically, explain the procedure, reference the active state of research, and use consultation framing for CTAs. Clinics cannot make disease treatment claims, imply FDA approval, or use testimonials describing condition resolution.
Are Autologous Exosome Procedures Outside FDA Jurisdiction?
Not necessarily. The autologous regulatory analysis is more nuanced and not fully settled. The minimal manipulation and homologous use criteria still apply. Consult qualified legal counsel before assuming an autologous protocol sits outside premarket approval requirements.
How Is Exosome Marketing Different From PRP Marketing?
PRP is a blood product outside 21 CFR Part 1271 and does not require a BLA. Exosome products are regulated as drugs and biological products requiring premarket approval. Disease claims about exosomes carry an additional layer of risk because they constitute marketing of an unapproved drug.
What Sourcing Practices Reduce Clinic Exposure?
Sourcing from suppliers who provide lot-level Certificates of Analysis, donor screening records, sterility testing documentation, and FDA registration information. Documentation does not equal product approval, and the distinction must be explicit in marketing.
Does State Law Affect Exosome Marketing Requirements?
State laws operate separately from federal regulations. Some states have additional rules for regenerative medicine marketing and informed consent. Federal and state compliance need to be considered together.
Key Takeaways
No exosome products are FDA approved. This is the foundational fact and has not changed since 2019.
The enforcement risk is in the marketing, not the existence of the service. Disease treatment claims, FDA approval implications, and condition-specific advertising are what trigger warning letters.
Exosome marketing is more restrictive than PRP marketing. Both prohibit disease claims, but exosomes carry the added layer of unapproved drug status.
Compliant language exists. Educational descriptions, process information, research context, off-label disclosure, and consultation framing are all available. The middle path is real.
Sourcing matters. A clinic that uses products from suppliers in violation inherits exposure. Documentation standards protect the practice.
Legal counsel is not optional. Consult qualified legal counsel before launching any exosome marketing campaign or finalizing protocol-related copy.
Let’s Talk Strategy
If you offer exosome services and have been told to either market them aggressively or avoid them entirely, neither approach serves the practice. Compliant exosome marketing is built on accurate language and process-based positioning. It can grow the practice. It just requires precision.
Regen Portal builds marketing strategies for regenerative medicine clinics that account for these compliance realities from the first piece of content forward.
For a conversation about your specific situation, reach out at [email protected].
For deeper dives on compliance and marketing strategy, subscribe to the Regen Portal YouTube channel: https://www.youtube.com/@oatellez
About Regen Portal
Regen Portal is a marketing company serving the regenerative medicine industry. We provide SEO, content creation, social media management, paid advertising, website development, and branding services for clinics, manufacturers, distributors, and independent providers. Some strategies discussed in our educational content align with services we offer. For more information, contact us.
About the Author
Oscar Tellez is the founder of Regen Portal, a marketing company built for the regenerative medicine industry. With over 15 years of experience spanning clinical operations, product distribution, and digital marketing, Oscar has helped hundreds of practices, manufacturers, and distributors grow through compliant, high-performance marketing strategies. He holds a B.S. in Exercise Physiology and Health Promotion from Florida Atlantic University.
